The "Major Depressive Disorder (MDD) - Market Insights, Epidemiology, and Market Forecast - 2028" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MDD in the 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Major Depressive Disorder (MDD) from 2017 to 2028 segmented by seven emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2017-2028
Major Depressive Disorder (MDD) - Disease Understanding
A major depressive disorder is the most prevalent and disabling form of depression. In addition to the immediate symptoms of depression, MDD results in the poor quality of life overall decreased productivity and can increase mortality from suicide. Depression does not have a single cause. It can be triggered, or it may occur spontaneously without being associated with a life crisis, physical illness or another risk.
Social difficulties including stigma, loss of employment, and marital conflict as a result of depression can also occur. Anxiety Posttraumatic Stress Disorder (PTSD), and substance misuse are common co-occurring conditions that may worsen the existing depression and complicate treatment.
The Major Depressive Disorder (MDD) market report gives a thorough understanding of the Major Depressive Disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms for Major Depressive Disorder in the 7MM.
Major Depressive Disorder Epidemiology
The Major Depressive Disorder (MDD) epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven countries in the report. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (12 months prevalent cases of Major Depressive Disorder, age-specific cases of Major Depressive Disorder, gender-specific cases of Major Depressive Disorder, severity-specific cases of Major Depressive Disorder, treatable cases of Major Depressive Disorder, relapsed/refractory cases of Major Depressive Disorder) scenario of Major Depressive Disorder (MDD) in the 7MM covering United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017-2028.
According to the publisher, a total of 12 months of the prevalent population of Major Depressive Disorder in 7 major markets was observed to be 34,011,712 cases in 2017.
Major Depressive Disorder Drug Chapters
This segment of the Major Depressive Disorder report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Antidepressants comprise the treatment market of MDD. The treatment of MDD is segmented on the basis of various phases includes the acute phase, continuation phase, and maintenance phase of treatment. Different types of depression require different treatment. For moderate to more severe depression, Pharmacological treatments are likely to be required, in combination with these other treatments.
Major Depressive Disorder Market Outlook
The Major Depressive Disorder market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs,
drivers and barriers and demand for better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, the market of Major Depressive Disorder in 7MM was found to be USD 9.3 Billion in 2017 and is expected to increase during the course of the study period (2017-2028). United States accounts for the largest market size of Major Depressive Disorder, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Major Depressive Disorder Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Major Depressive Disorder Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Major Depressive Disorder Report Key Strengths
- 9 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Key Cross Competition
- Market Size by Therapies
- Drugs Uptake
Major Depressive Disorder Report Assessment
- Pipeline Product Profiles
- Key Products and Key Players
- Market Drivers and Barriers
Key Benefits
- This report will help to develop Business Strategies by understanding the trends shaping and driving Major Depressive Disorder market
- Organize sales and marketing efforts by identifying the best opportunities for Major Depressive Disorder market
- To understand the future market competition in the Major Depressive Disorder market.
Table of Contents
1. Key Insights
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ACADIA Pharmaceuticals
- Alkermes
- Allergen
- Axsome Therapeutics
- BlackThorn Therapeutics
- Chase Therapeutics
- Fabre-Kramer Pharmaceuticals
- Gedeon Richter
- Janssen Pharmaceuticals
- Lundbeck A/S
- Luye Pharma
- Minerva Neurosciences
- Otsuka Pharmaceutical
- Pfizer
- SAGE Therapeutics
- Takeda Pharmaceuticals